openPR Logo
Press release

Hidradenitis Suppurativa (HS) Patient Pool Analysis Market Massive Growth opportunity Ahead

09-04-2025 02:49 PM CET | Health & Medicine

Press release from: Exactitude Consultancy

Hidradenitis Suppurativa (HS) Patient Pool Analysis Market

Hidradenitis Suppurativa (HS) Patient Pool Analysis Market

Introduction
Hidradenitis Suppurativa (HS) is a chronic, inflammatory skin condition characterized by painful nodules, abscesses, and sinus tract formation in areas such as the armpits, groin, and under the breasts. The disease is progressive, debilitating, and associated with significant physical and psychological burden, often leading to social stigma and reduced quality of life.

Historically underdiagnosed, HS is now gaining increased clinical recognition as awareness grows among healthcare providers and patients. Advances in dermatology, combined with the rising adoption of biologics and patient support programs, are shaping a clearer understanding of the HS patient pool.
In 2024, the global HS patient pool is estimated at 14.5 million individuals. By 2034, it is projected to rise to 19.8 million, reflecting a CAGR of 3.2%. The increase is driven by rising obesity rates, genetic predisposition, lifestyle factors, and improved diagnostic practices.

Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71552

Market Overview
• Global Patient Pool (2024): ~14.5 million individuals
• Forecast (2034): ~19.8 million individuals
• CAGR (2024-2034): 3.2%
• Key Growth Drivers:
o Growing awareness and earlier diagnosis of HS.
o Rising obesity and metabolic syndrome prevalence, strong risk factors for HS.
o Expansion of biologic therapies such as TNF-α and IL-17 inhibitors.
o Patient advocacy groups raising disease visibility.
• Key Challenges:
o High rates of underdiagnosis and misdiagnosis (up to 50% of cases remain unrecognized).
o Limited number of approved therapies; reliance on off-label treatments.
o Psychological burden impacting adherence to therapy.
• Leading Players in HS Treatment and Research: AbbVie, Novartis, Eli Lilly, UCB, Incyte, InflaRx, and Chemocentryx.

Segmentation Analysis
By Demographics
• Age Group: Adolescents & Young Adults (15-34 years), Adults (35-54 years), Elderly (55+)
• Gender: Female, Male (higher prevalence in women but often more severe in men)
• Risk Factors: Obesity, family history, smoking, metabolic disorders

By Diagnosis Method
• Clinical Examination
• Imaging (Ultrasound, MRI for severe cases)
• Biopsy (in rare diagnostic challenges)
• Symptom-Based Patient-Reported Tools (Hurley staging, IHS4 scoring)

By Treatment Status
• Untreated/Undiagnosed Patients
• Patients on Conventional Therapy (antibiotics, retinoids, hormonal therapy)
• Patients on Biologics (adalimumab, secukinumab, bimekizumab, pipeline agents)
• Patients on Surgical Intervention (laser therapy, excision)

By End Use
• Hospitals & Dermatology Clinics
• Specialty Skin Centers
• Research & Academic Institutes
• Patient Advocacy Organizations

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

Segmentation Summary:
Women aged 20-40 make up the largest share of the HS patient pool, highlighting the disease's early onset and chronic course. While most patients are managed with antibiotics and symptomatic therapies, biologics are the fastest-growing treatment category, offering targeted and durable relief for moderate-to-severe HS.

Explore Full Report here:
https://exactitudeconsultancy.com/reports/71552/hidradenitis-suppurativa-patient-pool-analysis-market

Regional Analysis
North America
• Largest share of diagnosed patient pool (~30%).
• High prevalence due to obesity, smoking, and advanced diagnostic capabilities.
• Strong presence of biologic adoption, particularly adalimumab.
Europe
• Second-largest pool with active patient registries in Germany, France, and the UK.
• EU initiatives to expand access to biologics and support rare disease recognition.
Asia-Pacific (APAC)
• Fastest-growing region with rising obesity rates and increased awareness in Japan, China, and India.
• Significant underdiagnosis, but rapid improvement through public health initiatives.
Latin America
• Brazil and Mexico lead in patient numbers, though access to biologics remains limited.
• Reliance on antibiotics and surgery is more common due to cost constraints.
Middle East & Africa (MEA)
• Smallest diagnosed patient pool but increasing prevalence due to lifestyle shifts.
• GCC nations investing in dermatology clinics and rare disease care.

Regional Summary:
While North America and Europe dominate diagnosed populations, Asia-Pacific will grow fastest (CAGR ~4.1%), reflecting a large undiagnosed base and rising healthcare investments.

Market Dynamics
Key Growth Drivers
• Improved Disease Awareness: Campaigns and education for healthcare professionals accelerating early recognition.
• Rising Risk Factors: Increasing obesity, smoking, and sedentary lifestyles expanding the patient base.
• Biologic Breakthroughs: Drugs like Humira (adalimumab) and pipeline IL-17/IL-23 inhibitors transforming care.
• Patient Advocacy: Organizations pushing for recognition of HS as a severe chronic disease.

Key Challenges
• High Underdiagnosis Rates: Many patients are misdiagnosed with boils or acne.
• Treatment Limitations: Few approved drugs, reliance on off-label use.
• Cost Barriers: Biologics remain expensive, limiting access in emerging markets.

Latest Trends
• Pipeline Expansion: IL-17 inhibitors (secukinumab, bimekizumab) showing strong clinical promise.
• Digital Health: Mobile apps and teledermatology supporting self-management.
• Surgical Innovations: Laser therapy and minimally invasive excisions gaining ground.
• Quality of Life Studies: Increasing focus on psychological burden and mental health support.

Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71552

Competitor Analysis

Key Companies in HS Market:
• AbbVie - Humira (adalimumab), only FDA-approved biologic for HS.
• Novartis - Secukinumab, under study for HS.
• Eli Lilly - Pipeline biologics targeting IL-17/IL-23 pathways.
• UCB - Biologic therapies in development for inflammatory skin diseases.
• Incyte - Immunology-focused pipeline.
• InflaRx - Developing novel immunomodulators.
• Chemocentryx - Investigational therapies in autoimmune diseases.

Competitive Summary:
AbbVie dominates today with Humira, but emerging biologics from Novartis, Lilly, and UCB are set to intensify competition by 2030. Biotech firms like InflaRx and Incyte add innovation, while academic-industry collaborations accelerate HS research.

Conclusion
The Hidradenitis Suppurativa (HS) Patient Pool Analysis Market highlights both the burden and opportunity in dermatology. By 2034, the patient pool will expand to nearly 19.8 million individuals, reflecting a growing global challenge that requires innovation and awareness.

Key Takeaways:
• Global patient pool: 14.5M (2024) → 19.8M (2034).
• CAGR: 3.2%.
• Women aged 20-40 most affected; underdiagnosis remains a critical issue.
• Biologics are the fastest-growing therapy segment, reshaping treatment paradigms.
• North America and Europe lead today, but APAC will grow fastest (4.1% CAGR).

This report is also available in the following languages : Japanese (化膿性汗腺炎患者プール分析市場), Korean (히드라데니티스 화농증 환자 풀 분석 시장), Chinese (化脓性汗腺炎患者群体分析市场), French (Analyse du marché des patients atteints d'hidradénite suppurée), German (Marktanalyse des Patientenpools für Hidradenitis suppurativa), and Italian (Analisi del mercato dei pazienti con idrosadenite suppurativa), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71552

Our More Reports:

Nutraceuticals Market
https://exactitudeconsultancy.com/reports/72380/nutraceuticals-market

Voluntary Carbon Credit Market
https://exactitudeconsultancy.com/reports/72383/voluntary-carbon-credit-market

Companion Animal Health Market
https://exactitudeconsultancy.com/reports/72382/companion-animal-health-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.

https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hidradenitis Suppurativa (HS) Patient Pool Analysis Market Massive Growth opportunity Ahead here

News-ID: 4170345 • Views:

More Releases from Exactitude Consultancy

SSG Hospital launches an AI-powered oncology chatbot
SSG Hospital launches an AI-powered oncology chatbot
The global AI in Oncology Market is rapidly emerging as one of the most transformative frontiers in healthcare, combining advanced machine learning, big data analytics, and clinical expertise to fight cancer. With oncology representing one of the most complex medical domains, artificial intelligence (AI) is reshaping how clinicians detect, diagnose, and treat cancer. AI is accelerating drug discovery, enhancing diagnostic imaging, enabling personalized treatment recommendations, and improving patient monitoring. As
Orion and Abilita Therapeutics Announce Research Partnership to Create Next-Generation Antibody Therapeutics for Pain and Oncology
Orion and Abilita Therapeutics Announce Research Partnership to Create Next-Gene …
The global Next-Generation Antibody Therapeutics Market is experiencing rapid growth as pharmaceutical and biotechnology companies push the boundaries of antibody engineering to deliver safer, more effective, and highly targeted therapies. Unlike conventional monoclonal antibodies, next-generation formats-such as bispecific antibodies, antibody-drug conjugates (ADCs), antibody fragments, and engineered scaffolds-offer enhanced specificity, improved pharmacokinetics, and novel mechanisms of action. These innovations are revolutionizing treatment landscapes in oncology, autoimmune disorders, infectious diseases, and rare
Prospects for the NAMPT Inhibitors Market in 2025-2034 | Pfizer Inc., Novartis AG, and Johnson & Johnson
Prospects for the NAMPT Inhibitors Market in 2025-2034 | Pfizer Inc., Novartis A …
The NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitor Market is gaining momentum as researchers and biopharmaceutical companies explore novel therapeutic strategies targeting cellular metabolism and inflammatory pathways. NAMPT, a key enzyme in the NAD+ biosynthesis pathway, has been implicated in cancer cell survival, immune regulation, and metabolic disorders. Inhibitors of NAMPT have emerged as promising candidates for oncology, autoimmune conditions, and age-related diseases. With clinical trials expanding and increasing R&D investments, the NAMPT
Acute lymphoblastic leukemia: a comprehensive review and 2025 latest update
Acute lymphoblastic leukemia: a comprehensive review and 2025 latest update
Introduction Acute lymphoblastic leukemia (ALL) is an aggressive cancer of the blood and bone marrow that primarily affects white blood cell precursors. While relatively rare compared to other cancers, it is the most common type of cancer in children, though it also affects adults, where prognosis is often poorer. The management of ALL has improved significantly in recent decades due to advances in chemotherapy regimens, targeted therapies, and immunotherapies such as CAR-T

All 5 Releases


More Releases for Patient

Patient Portal Market: Empowering Patient-Centric Healthcare
In recent years, the global Patient Portal Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on Patient Portal Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of business matrices including
Patient Portal Market: Empowering Patient-Centric Healthcare
In recent years, the global Patient Portal Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on Patient Portal Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of business matrices including
Future Growth: Patient Advocacy Solutions Market Sees Promising Growth in 2024 | …
The latest research study released by Worldwide Market Reports on "Patient Advocacy Solutions Market 2024" holds tons of experience in offering comprehensive and accurate analysis of global as well as regional markets. The analysts and researchers authoring the report have provided a deeper competitive analysis of the Patient Advocacy Solutions market along with exhaustive company profiling of leading market players. This research study of the Patient Advocacy Solutions Market involved
Factors Influencing Global Digital Patient Empowerment Services Market through 2 …
The worldwide "Digital Patient Empowerment Services Market" 2023 Research Report presents a professional and complete analysis of the Global Digital Patient Empowerment Services Market in the current situation. This report includes development plans and policies along with Digital Patient Empowerment Services manufacturing processes and price structures. the reports 2023 research report offers an analytical view of the industry by studying different factors like Digital Patient Empowerment Services Market growth, consumption
10-11-2022 | Health & Medicine
Fact.MR
Growing Demand For Patient Handling Equipment & Patient Positioning Devices To A …
As per Fact.MR, a market research and competitive intelligence provider, the global patient lateral transfer devices market is anticipated to top US$ 500 Mn by 2031, progressing at a CAGR of 7% over the forecast period of 2021 to 2031. Lateral transfer is a repositioning aid or equipment that reduces friction and makes it easier and safer to transfer patients laterally. Patient lateral transfer devices are designed to stay with the
Patient Perspectives - Patient Reported Outcomes Drive Drug Development, But Imp …
GBI Research, the leading business intelligence provider, has released its latest research, Patient Perspectives Patient Reported Outcomes Drive Drug Development, but Improving Patient Involvement Remains a Challenge. The report examines the role of patients in changing the research agenda and helping pharma companies to bring effective medicines that meet real unmet medical needs into the market place. It explores the use of patient reported outcomes in drug development, with a